Just two comments that should be be considered or corrected with...

Just two comments that should be be considered or corrected with the above.

The COGS is running at 67% not 75%. This an impairment of 22% on the prior comparable period where COGS was around 44% likely due to the drop off of OEM sales which would have higher gross profit margins on them. Furthermore, yes the company was burning through cash reserves in the lead up to 31st Dec but the half yearly does not reflect the material improvement in their cash balance running into Q3 due to COVID sales, where the balance actually increased by $2.2million to $15.8m.

Notwithstanding the above comments, I fully agree with your assessment that the company needs to look beyond covid and sure up some major sales channels for its HIV & OEM product lines. Hence why the market may be pricing the stock the way it is at this current point in time, because without the covid sales there's not much meat left on the bone.